Published in Clin Exp Nephrol on June 02, 2015
Nutrition in Cardioskeletal Health. Adv Nutr (2016) 0.75
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int (2002) 9.29
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet (2013) 4.58
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int (2005) 3.71
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int (2004) 3.12
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
The case against calcium-based phosphate binders. Clin J Am Soc Nephrol (2006) 2.38
Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr (2008) 2.22
The emerging role of phosphate in vascular calcification. Kidney Int (2009) 2.14
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl (2003) 2.04
Magnesium - its role in CKD. Nefrologia (2013) 2.04
Increased parathyroid expression of klotho in uremic rats. Kidney Int (2010) 2.00
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int (2012) 1.84
Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol (2008) 1.75
Intestinal phosphate absorption in a model of chronic renal failure. Kidney Int (2007) 1.58
Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer. Hemodial Int (2014) 1.38
Phosphate additives in food--a health risk. Dtsch Arztebl Int (2012) 1.33
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract (2008) 1.29
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol (2008) 1.25
The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol (2010) 1.21
Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol (2007) 1.19
Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol (2008) 1.18
Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol (2006) 1.16
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin (2007) 1.15
Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest (1989) 1.12
Oral phosphate binders. Kidney Int (2009) 1.10
Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.09
Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol (2006) 1.07
Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant (2013) 1.06
Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol (2011) 1.02
Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant (1997) 1.01
Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol (2008) 1.00
Luminal fructose inhibits rat intestinal sodium-phosphate cotransporter gene expression and phosphate uptake. Am J Clin Nutr (2008) 0.94
Endotoxin-binding affinity of sevelamer hydrochloride. Am J Nephrol (2008) 0.92
The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron (1982) 0.90
The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol (2015) 0.89
A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant (2013) 0.88
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant (2008) 0.88
Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One (2014) 0.88
Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant (2014) 0.86
Adynamic bone disease-bone and beyond. NDT Plus (2008) 0.86
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol (2011) 0.86
Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol (2013) 0.84
Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. Ren Fail (2010) 0.84
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health (2011) 0.84
Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int Suppl (2005) 0.83
FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant (2012) 0.81
Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool. J Nephrol (2014) 0.81
Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant (2013) 0.81
Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control. Int J Nephrol (2011) 0.80
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol (2011) 0.80
Impaired response of FGF-23 to oral phosphate in patients with type 2 diabetes: a possible mechanism of atherosclerosis. J Clin Endocrinol Metab (2012) 0.80
Role of NPT2b in health and chronic kidney disease. Curr Opin Nephrol Hypertens (2014) 0.79
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag (2008) 0.79
Dietary phosphate restriction in dialysis patients: a new approach for the treatment of hyperphosphataemia. Nutr Metab Cardiovasc Dis (2010) 0.78
Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant (2009) 0.78
Salivary phosphorus binding: a novel approach to control hyperphosphatemia. J Am Soc Nephrol (2009) 0.78
Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D (2013) 0.78
Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence. Br J Clin Pharmacol (2013) 0.78
Nutritional therapy, phosphate control and renal protection. Nephron Clin Pract (2014) 0.78
Next-generation phosphate binders: focus on iron-based binders. Drugs (2014) 0.78
Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int (2008) 0.78
Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. Ther Clin Risk Manag (2014) 0.77
Phosphate binders: hold the calcium? Clin J Am Soc Nephrol (2006) 0.76
Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride. Clin Nephrol (2010) 0.76
Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med (2008) 0.76
Gadolinium and lanthanum: a iatrogenic transmetallation? Clin Biochem (2008) 0.76
The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant (2013) 0.75
Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol (2014) 0.75
The ubiquitous nature and elusive role of phosphorus and vascular calcification. Am J Kidney Dis (2009) 0.75
[Is lanthanum carbonate a safe drug?]. Clin Calcium (2009) 0.75
Spanish nephrologists and the management of mineral and bone metabolism disorders in chronic kidney disease. Nefrologia (2014) 0.75
[Lanthanum carbonate in clinical practice]. Nefrologia (2008) 0.75
[Calcimimetic drugs in stage 3-5 chronic kidney disease]. Pol Merkur Lekarski (2012) 0.75